Percutaneous internal fixation with Y-STRUT® device to prevent both osteoporotic and pathological hip fractures: a prospective pilot study

François H Cornelis, Lambros Tselikas, Thibault Carteret, Bruno Lapuyade, Thierry De Baere, Jean Charles Le Huec, Frédéric Deschamps, François H Cornelis, Lambros Tselikas, Thibault Carteret, Bruno Lapuyade, Thierry De Baere, Jean Charles Le Huec, Frédéric Deschamps

Abstract

Background: We studied Y-STRUT® (Hyprevention, France), a new percutaneous internal fixation device, in combination with bone cementoplasty to prevent hip fracture.

Methods: Between February 2013 and February 2015, a total of 16 femoral necks in 4 osteoporotic and 12 oncologic patients have been considered for prophylactic consolidation in this prospective multicentre pilot study involving 4 different hospitals. These consolidations were performed percutaneously under fluoroscopic guidance using Y-STRUT®, a dedicated internal fixation device. For osteoporotic patients, orthopaedic surgeons performed the prophylactic consolidations immediately after surgical treatment of a hip fracture (same anaesthesia) in the opposite side. For oncologic patients, without current hip fracture but considered at risk (Mirels score ≥8), interventional radiologists performed the procedures. We report the preliminary results of feasibility, safety and tolerance of these preventive consolidations using Y-STRUT®.

Results: Four patients (mean 83 years old) had prophylactic consolidation because of a severe osteoporosis (mean T-score -3.30) resulting in first hip fractures. Ten patients (mean 61 years old) were treated because of impending pathological fractures (mean Mirels score 9) related to femoral neck osteolytic metastases. All the procedures were performed with success. Wound healing was achieved in all cases with no access site complication. Radiographic exams performed at 3 months follow-up revealed that Y-STRUT® was well integrated in the bone. For the osteoporotic cohort, mean pain was 0.9 ± 0.7 at 3 weeks. For the oncologic cohort, it decreases from 3.6 ± 2.9 at baseline to 2.4 ± 0.9 at 2 months.

Conclusions: Preliminary results demonstrate the feasibility and safety of Y-STRUT® implantation as well as the tolerance of the device.

Keywords: Biomechanical reinforcement; Bone metastases; Osteoporosis; Pathological hip fracture; Prophylactic consolidation; Proximal femur.

Figures

Fig. 1
Fig. 1
Y-STRUT® implants (schematic and x-ray views)
Fig. 2
Fig. 2
Percutaneous approach
Fig. 3
Fig. 3
Radiotransparent implant has been implemented. The bone metastasis is being filled with PMMA bone cement

References

    1. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367(9527):2010–8. doi: 10.1016/S0140-6736(06)68891-0.
    1. Cooper C, Campion G, Melton LJ., III Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2(6):285–9. doi: 10.1007/BF01623184.
    1. Ekman EF. The role of the orthopaedic surgeon in minimizing mortality and morbidity associated with fragility fractures. J Am Acad Ortho Surg. 2010;18(5):278–85. doi: 10.5435/00124635-201005000-00004.
    1. Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P. Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001. J Bone Miner Res. 2009;24(7):1299–307. doi: 10.1359/jbmr.090207.
    1. Bawa HS, Weick J, Dirschl DR. Anti-osteoporotic therapy after fragility fracture lowers rate of subsequent fracture: analysis of a large population sample. J Bone Joint Surg Am. 2015;97(19):1555–62. doi: 10.2106/JBJS.N.01275.
    1. Heini PF, Franz T, Fankhauser C, Gasser B, Ganz R. Femoroplasty-augmentation of mechanical properties in the osteoporotic proximal femur: a biomechanical investigation of PMMA reinforcement in cadaver bones. Clin Biomech. 2004;19(5):506–12. doi: 10.1016/j.clinbiomech.2004.01.014.
    1. Sutter EG, Mears SC, Belkoff SM. A biomechanical evaluation of femoroplasty under simulated fall conditions. J Orthop Trauma. 2010;24(2):95–9. doi: 10.1097/BOT.0b013e3181b5c0c6.
    1. Giannini S, Luciani D, Chiarello E, Cadossi M, Tedesco G, Hoque M, Gnudi S. Osteosynthetic improvement of osteoporotic bone: prevention surgery. Clin Cases Miner Bone Metab. 2011;8(1):51–4.
    1. Schneiderbauer MM, von Knoch M, Schleck CD, Harmsen WS, Sim FH, Scully SP. Patient survival after hip arthroplasty for metastatic disease of the hip. J Bone Joint Surg Am. 2004;86-A(8):1684–9. doi: 10.2106/00004623-200408000-00011.
    1. Parker MJ, Khan AZ, Rowlands TK. Survival after pathological fractures of the proximal femur. Hip Int. 2011;21(5):526–30. doi: 10.5301/HIP.2011.8654.
    1. Ristevski B, Jenkinson RJ, Stephen DJ, Finkelstein J, Schemitsch EH, McKee MD, Kreder HJ. Mortality and complications following stabilization of femoral metastatic lesions: a population-based study of regional variation and outcome. Can J Surg. 2009;52(4):302–8.
    1. Deschamps F, Farouil G, Hakime A, Teriitehau C, Barah A, de Baere T. Percutaneous stabilization of impending pathological fracture of the proximal femur. Cardiovasc Intervent Radiol. 2012;35(6):1428–32. doi: 10.1007/s00270-011-0330-8.
    1. Deschamps F, de Baere T, Hakime A, Pearson E, Farouil G, Teriitehau C, Tselikas L. Percutaneous osteosynthesis in the pelvis in cancer patients. Eur Radiol. 2016;26(6):1631–9. doi: 10.1007/s00330-015-3971-1.
    1. Tian QH, He CJ, Wu CG, Li YD, Gu YF, Wang T, Xiao QP, Li MH. Comparison of percutaneous cementoplasty with and without interventional internal fixation for impending malignant pathological fracture of the proximal femur. Cardiovasc Intervent Radiol. 2015;39(1):81–9. doi: 10.1007/s00270-015-1133-0.
    1. Mirels H. Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures: 1989. Clin Orthop Relat Res. 2003;415(Suppl):S4–13.
    1. Szpalski M, Gunzburg R, Aebi M, Delimoge C, Graf N, Eberle S, Vienney C. A new approach to prevent contralateral hip fracture: evaluation of the effectiveness of a fracture preventing implant. Clin Biomech. 2015;30(7):713–9. doi: 10.1016/j.clinbiomech.2015.05.001.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다